Journal
NATURE MEDICINE
Volume 27, Issue 6, Pages 981-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41591-021-01325-6
Keywords
-
Funding
- Cedars-Sinai Medical Center
- Erika J. Glazer Family Foundation
- F. Widjaja Family Foundation
- Helmsley Charitable Trust
- National Institutes of Health [U54-CA260591, K23-HL153888]
Ask authors/readers for more resources
Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
